Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
ZYDUSLIFEBSEZYDUS LIFESCIENCES LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 11 Aug, 2026 · 13:24 IST

Zydus Lifesciences Q1 FY27 results: revenue up 22%, profit declines on costs

Revenue Growth 20pctExceptional ItemEbitda Margin CompressionResults View source PDFExplain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+6.8%Reaction day
₹1119.00
prior close
₹1162.60
announcement price
In-mkt
timing
Nifty 100market-0.4%+7.2% vs market
Pharmaceuticals peers, median of 164sector+0.1%+6.8% vs sector

On the reaction day the stock moved 7.2 pts more than Nifty 100 and 6.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.9
10m
-2.5
15m
-3.0
30m
+0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+6.8-0.4+7.2+0.1+6.8
Next day
+7.2-0.5+7.7-0.5+7.7
2d
+4.7-0.6+5.4+0.1+4.6
3d
+1.4-0.8+2.2-0.5+2.0
4d
+1.1-1.1+2.2-1.1+2.2
5d
-0.3-1.5+1.2-0.7+0.4
1w
-0.3-1.3+1.0-1.2+0.9
15d
+3.8-2.2+6.1-0.8+4.7
1m
+0.0-4.6+4.6+1.1-1.1
2m
+1.4-8.9+10.3-3.1+4.5
3m
—————
UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences Q1 FY27: consolidated revenue rose 22% YoY to 80,170 million INR, but net profit fell 36% to 9,398 million due to higher costs from recent acquisitions and 182 million in exceptional items including Assertio severance and antitrust settlement. Standalone revenue grew 11% to 28,722 million; standalone PAT declined to 3,396 million. Company completed 11,063 million INR share buyback during the quarter.

Likely market impact

Mixed results: strong revenue growth from acquisitions but sharp PAT decline on integration costs and one-time charges may pressure near-term sentiment.